Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03136068 · ClinicalTrials.gov registry record · Phase 4
Intrafetal Digoxin as an Adjuvant for Dilation and Evacuation at 20 to 24 Weeks' Gestation
A Phase 4 study, sponsored by University of California, San Francisco.
- Completed
- Registry status
- Phase 4
- Development phase
- 178
- Enrollment target
NCT03136068 is a Phase 4 study that has completed, run by University of California, San Francisco. The registered enrollment target is 178 participants.
The verdict
NCT03136068, a Phase 4 study, has completed, sponsored by University of California, San Francisco.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 178 participants
- Enrollment target
Study Summary
This is a research study to measure the effect of digoxin injection on Dilation and Evacuation (D\&E) procedure duration. Digoxin is the most commonly used feticidal agent among family planning subspecialists, and is commonly used for a variety of reasons including provider preference, patient preference, and concerns over legal status of later D\&E procedures. There have been several studies on digoxin administration, adverse effects, and impact on the D\&E procedure, but doctors want to clarify how digoxin effects D\&E procedure time, if at all.
Interventions
- DRUG Placebo
- DRUG Digoxin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 178 participants |
| Start Date | 2017-02-23 |
| Est. Completion | 2018-05-31 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03136068
The ClinicalTrials.gov registry entry for NCT03136068 describes a study currently listed as completed, categorized as Phase 4. The registered enrollment target is 178 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of California, San Francisco, which has 1,713 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03136068 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03136068 about?
NCT03136068 is a clinical study titled "Intrafetal Digoxin as an Adjuvant for Dilation and Evacuation at 20 to 24 Weeks' Gestation". This is a research study to measure the effect of digoxin injection on Dilation and Evacuation (D\&E) procedure duration. Digoxin is the most commonly used feticidal agent among family planning subspecialists, and is commonly used for a variety of reasons including provider preference, patient prefe...
What is the current status of trial NCT03136068?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 178 participants. The study started on 2017-02-23. Estimated completion is 2018-05-31.
What interventions are being tested in trial NCT03136068?
The interventions under investigation include: Placebo (DRUG), Digoxin (DRUG).
Who is sponsoring clinical trial NCT03136068?
This trial is sponsored by University of California, San Francisco, which has 1,713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.